AU2023257557A1 - Therapeutic compositions with imino sugars for the treatment of diseases with accumulation of heparan sulfate - Google Patents

Therapeutic compositions with imino sugars for the treatment of diseases with accumulation of heparan sulfate Download PDF

Info

Publication number
AU2023257557A1
AU2023257557A1 AU2023257557A AU2023257557A AU2023257557A1 AU 2023257557 A1 AU2023257557 A1 AU 2023257557A1 AU 2023257557 A AU2023257557 A AU 2023257557A AU 2023257557 A AU2023257557 A AU 2023257557A AU 2023257557 A1 AU2023257557 A1 AU 2023257557A1
Authority
AU
Australia
Prior art keywords
iminosugars
accumulation
mondnj
treatment
nbdnj
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023257557A
Other languages
English (en)
Inventor
Massimo D'AGOSTINO
Valeria DE PASQUALE
Anna ESPOSITO
Annalisa GUARAGNA
Luigi Michele PAVONE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swell Therapeutics LLC
Original Assignee
Swell Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Swell Therapeutics LLC filed Critical Swell Therapeutics LLC
Publication of AU2023257557A1 publication Critical patent/AU2023257557A1/en
Assigned to Swell Therapeutics LLC reassignment Swell Therapeutics LLC Request for Assignment Assignors: D'AGOSTINO, Massimo, DE PASQUALE, Valeria, ESPOSITO, Anna, GUARAGNA, Annalisa, PAVONE, Luigi Michele
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2023257557A 2022-04-20 2023-04-18 Therapeutic compositions with imino sugars for the treatment of diseases with accumulation of heparan sulfate Pending AU2023257557A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT102022000007808A IT202200007808A1 (it) 2022-04-20 2022-04-20 Composizioni terapeutiche per malattie causate da accumulo di eparan solfato
IT102022000007808 2022-04-20
PCT/EP2023/059966 WO2023203004A1 (en) 2022-04-20 2023-04-18 Therapeutic compositions with imino sugars for the treatment of diseases with accumulation of heparan sulfate

Publications (1)

Publication Number Publication Date
AU2023257557A1 true AU2023257557A1 (en) 2024-12-05

Family

ID=82483266

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023257557A Pending AU2023257557A1 (en) 2022-04-20 2023-04-18 Therapeutic compositions with imino sugars for the treatment of diseases with accumulation of heparan sulfate

Country Status (9)

Country Link
US (1) US20250255856A1 (enExample)
EP (1) EP4511032A1 (enExample)
JP (1) JP2025513384A (enExample)
CN (1) CN119136803A (enExample)
AU (1) AU2023257557A1 (enExample)
CA (1) CA3249619A1 (enExample)
IT (1) IT202200007808A1 (enExample)
MX (1) MX2024012934A (enExample)
WO (1) WO2023203004A1 (enExample)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2083205C1 (ru) 1994-01-19 1997-07-10 Товарищество с ограниченной ответственностью предприятие "БИОМ" Способ лечения мукополисахаридоза
RU2196988C2 (ru) 2000-04-19 2003-01-20 Государственный новосибирский областной клинический диагностический центр Способ диагностики мукополисахаридозов
US20040204379A1 (en) * 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
AU2002241853A1 (en) 2001-01-12 2002-07-24 Oxford Glycosciences (Uk) Ltd. Mucopolysaccharidosis therapies
JP2003265196A (ja) 2002-03-15 2003-09-24 Seikagaku Kogyo Co Ltd ムコ多糖症のスクリーニング方法
AUPS293002A0 (en) 2002-06-14 2002-07-04 Women's And Children's Hospital Identification of oligosaccharides and their use in the diagnosis and evaluation of mucopolysaccharidoses and other related disorders
KR100762945B1 (ko) 2004-09-08 2007-10-04 진동규 동물 세포주를 이용한 이듀로네이트-설파타제의 발현 방법및 그 발현을 위한 세포주
PL377180A1 (pl) 2005-09-21 2007-04-02 Instytut Farmaceutyczny Zastosowanie izoflawonów i ich pochodnych w leczeniu mukopolisacharydoz
US8105788B2 (en) 2005-12-08 2012-01-31 The University Of British Columbia Mucopolysaccharidosis (MPS) diagnostic methods, systems, kits and assays associated therewith
US20070161074A1 (en) 2005-12-27 2007-07-12 Daiichi Pharmaceutical Co., Ltd. Diagnostic method of mucopolysaccharidoses
KR101497194B1 (ko) * 2009-09-04 2015-02-27 유나이티드 세러퓨틱스 코오포레이션 오르토믹소바이러스 감염의 치료 방법
AU2010366066B2 (en) 2010-12-22 2016-01-14 Fondazione Telethon Therapeutic strategies to treat CNS pathology in mucopolysaccharidoses
WO2012177778A1 (en) 2011-06-20 2012-12-27 Mount Sinai School Of Medicine Anti-tnf- therapy for the mucopolysaccharidoses and other lysosomal disorders
HK1221871A1 (zh) * 2013-05-02 2017-06-16 The Chancellor, Masters And Scholars Of The University Of Oxford 使用亚氨基糖进行的糖脂抑制
WO2017201030A1 (en) * 2016-05-16 2017-11-23 Emergent Virology Llc Methods of treating viral infection

Also Published As

Publication number Publication date
IT202200007808A1 (it) 2023-10-20
MX2024012934A (es) 2024-12-06
CN119136803A (zh) 2024-12-13
EP4511032A1 (en) 2025-02-26
CA3249619A1 (en) 2023-10-26
US20250255856A1 (en) 2025-08-14
JP2025513384A (ja) 2025-04-24
WO2023203004A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
US20230321130A1 (en) Senolytic Compositions and Uses Thereof
JP2007502861A (ja) 抗菌方法及び組成物
D’Alonzo et al. N-Butyl-l-deoxynojirimycin (l-NBDNJ): Synthesis of an Allosteric Enhancer of α-Glucosidase Activity for the Treatment of Pompe Disease
JP2020037578A (ja) プロテオパチーの処置のためのベンジリデングアニジン誘導体の新規な治療的使用
De Pasquale et al. N-substituted l-Iminosugars for the treatment of Sanfilippo type B syndrome
AU2021269232B2 (en) Non-lysosomal glucosylceramidase inhibitors and uses thereof
EP4074696A1 (en) Compound as potassium channel regulator, and preparation and use thereof
US8178609B2 (en) Isoflavones for treating mucopolysaccharidoses
WO2023203004A1 (en) Therapeutic compositions with imino sugars for the treatment of diseases with accumulation of heparan sulfate
JP2022502486A (ja) 細菌感染の処置における使用のためのインダン誘導体
AU2019217292B2 (en) Novel compound for preventing or treating neurodegenerative disease and application thereof
EP3126333B1 (en) Pqsr modulators
WO2012048417A1 (en) Inhibitors of p75 receptor and their uses
US20220227802A1 (en) Antibacterial aminoglycoside derivatives
WO2021142312A1 (en) Methods and compositions related to heparinoids
RU2791317C2 (ru) Новая композиция для предупреждения или лечения нейродегенеративного расстройства и ее применение
Esposito Synthesis and biological evaluation of novel therapeutic candidates for the treatment of infectious and rare diseases
US10537545B2 (en) Ceramide derivatives as anticancer agents
KR101881115B1 (ko) 신규 2-치환된 테트라하이드로피란 또는 2-치환된 테트라하이드로퓨란 유도체 화합물, 이의 제조방법 및 이의 용도
EA045519B1 (ru) Антибактериальные производные аминогликозидов

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SWELL THERAPEUTICS LLC

Free format text: FORMER APPLICANT(S): PAVONE, LUIGI MICHELE; GUARAGNA, ANNALISA; DE PASQUALE, VALERIA; ESPOSITO, ANNA; D'AGOSTINO, MASSIMO